Nutrition Issues in Hematopoietic Stem Cell Transplantation: State of the Art

Abstract

There have been many changes in hematopoietic stem cell transplantation (HSCT) that affect the patient's nutrition support. In the early 1970s, allogeneic transplants were the most common types of HSCTs; today, autologous transplants are the most common. Bone marrow, peripheral blood, and umbilical cord blood all now serve as sources of stem cells. Conditioning therapies include myeloablative, reduced-intensity myeloablative, and nonmyeloablative regimens. New medications are being developed and used to minimize the toxicities of the conditioning therapy and to minimize infectious complications. Supportive therapies for renal and liver complications have changed. In the past, HSCT patients received parenteral nutrition (PN) throughout their hospitalization and sometimes as home therapy. Because of medical complications and cost issues associated with PN, many centers are now working to use less PN and increase use of enteral nutrition. The immunosuppressed diet has changed from a sterile diet prepared under laminar-flow hoods to a more liberal diet that avoids high-risk foods and emphasizes safety in food handling practices. This article will review these changes in HSCT and the impact of these changes on the nutrition support of the patient.

Get full access to this article

View all access options for this article.

References

International Bone Marrow Transplant Registry. Summary 2003 Slide Set 1 [International Bone Marrow Transplant Registry website]. Available at: http://www.ibmtr.org/newsletter/sums_update.html. Accessed June 7, 2005.

Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood. 2000 ;95:3702– 3709.

Couban S, Simpson DR, Barnett MJ, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood. 2002;100:1525– 1531.

Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the histocompatibility and alternate stem cell source working committee of the International Bone Marrow Transplant Registry. J Clin Oncol. 2004 ;22:4872– 4880.

Wall DA. Allogeneic peripheral blood versus bone marrow transplantation: children are small adults and more. J Clin Oncol. 2004;22:4865– 4866.

Ringden O, Labopin M, Gorin N, et al. Treatment with granulocyte colony stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft versus host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Tranplantation. J Clin Oncol. 2004 ;22:416– 423.

Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004 ;351:2265– 2275.

Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004 ;351:2276– 2285.

Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical cord blood from unrelated donors. N Engl J Med. 2001 ;344:1815– 1822.

10.

Jaroscak J, Goltry K, Smith A, et al. Augmentation of umbilical cord blood transplantation with ex vivo expanded umbilical cord blood cells: results of a phase I trial using the AastromReplicell system. Blood. 2003;101:5061– 5067.

11.

Shpall, EF, Quinones R, Giller R, et al. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant. 2002 ;8:368– 376.

12.

Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003 ;102:3447– 3454.

13.

Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99:1071– 1078.

14.

Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004 ;104:3535– 3542.

15.

Bornhauser M, Thiede C, Platzbecker U, et al. Dose reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res. 2001 ;7:2254– 2262.

16.

Georges G, Maris M, Sandmaier BM, et al. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases. Int J Hematol. 2002 ;76(suppl 1):184– 189.

17.

Facorro G, Sarrasague MM, Torti H, et al. Oxidative study of patients with total body irradiation: effects of amifostine treatment. Bone Marrow Transplant. 2004 ;33:793– 798.

18.

Clemens MR, Waladkhani AR, Bublitz K, Ehninger G, Gey KF. Supplementation with antioxidants prior to bone marrow transplantation. Wien Klin Wochenschr. 1997 ;109:771– 776.

19.

Bruemmer B, Patterson RE, Cheney C, Aker SN, Witherspoon RP. The association between vitamin C and vitamin E supplement use before hematopoietic stem cell transplant and outcomes to two years. J Am Diet Assoc. 2003;103:982– 990.

20.

Jonas CR, Puckett AB, Jones DP, et al. Plasma antioxidant status after high-dose chemotherapy: a randomized trial of parenteral nutrition in bone marrow transplantation patients. Am J Clin Nutr. 2000 ;72:181– 189.

21.

Murray SM, Pindoria S. Nutrition support for bone marrow transplant patients. Cochrane Database Syst Rev. 2002 ;2:CD002920 .

22.

Ziegler TR. Glutamine supplementation in bone marrow transplantation. Br J Nutr. 2002 ;87(suppl 1):S9– S15.

23.

Buchman A. The role of glutamine: counterpoint. Nutr Clin Pract. 2003;18:391– 396.

24.

Lenssen P, Bruemmer B, Aker SN, McDonald GB. Nutrient support in hematopoietic cell transplantation. JPEN J Parenter Enteral Nutr. 2001;25:219– 228.

25.

Pytlik R, Benes P, Patorkova M, et al. Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind, placebo controlled study. Bone Marrow Transplant. 2002 ;30:953– 961.

26.

Canovas G, Leon-Sanz M, Gomez P, et al. Oral glutamine supplements in autologous hematopoietic transplant: impact on gastrointestinal toxicity and plasma protein levels. Haematologica. 2000 ;85:1229– 1230.

27.

Piccirillo N, De Matteis S, Laurenti L, et al. Glutamine-enriched parenteral nutrition after autologous peripheral blood stem cell transplantation: effects on immune reconstitution and mucositis. Haematologica. 2003 ;88:192– 200.

28.

Gabriel DA, Shea T, Olajida O, Serody JS, Comeau T. The effect of oral mucositis on morbidity and mortality in bone marrow transplant. Semin Oncol. 2003 ;30:76– 83.

29.

Wardley AM, Jayson GC, Swindell R, et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haematopoietic progenitor rescue. Br J Haematol. 2000 ;110:292– 299.

30.

Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19:2201– 2205.

31.

Robien K, Schubert MM, Bruemmer B, Lloid ME, Potter JD, Ulrich CM. Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. J Clin Oncol. 2004;22:1268– 1275.

32.

Sonis ST, Elting LS, Keefe D, et al. Perspectives on cancer therapy-induced mucosal injury. Cancer. 2004 ;100(suppl):1995– 2025.

33.

Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004;100 (suppl):2026– 2046.

34.

Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590– 2598.

35.

US Food and Drug Administration. Palifermin (keratinocyte growth factor) [FDA website]. Available at: http://www.fda.gov/cder/drug/infopage/palifermin/. Accessed June 7, 2005.

36.

van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001 ;345:1359– 1367.

37.

Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc. 2004;79:992– 1000.

38.

Wolman SL, Anderson H, Marliss EB, Jeejeebhoy KN. Zinc in total parenteral nutrition: requirements and metabolic effects. Gastroenterology. 1979 ;76:458– 467.

39.

Cesaro S, Chinello P, Rossi L, et al. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer. 2000 ;8:504– 505.

40.

Salminen MK, Rautelin H, Tynkkynen S, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L rhamnosus GG. Clin Infect Dis. 2004 ;38:62– 69.

41.

Lherm T, Monet C, Nougiere B, et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med. 2002 ;28:797– 801.

42.

Strasser SI, McDonald GB. Gastrointestinal and hepatic complications. In: Blume KG, Forman SJ, Applebaum FR, eds. Thomas' Hematopoietic Cell Transplantation. 3^rd ed. Oxford, England: Blackwell Publishing Ltd; 2004:769– 810.

43.

A.S.P.E.N. Board of Directors and Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN J Parenter Enteral Nutr 2002 ; 26(suppl)30SA– 33SA.

44.

Hathcock JN, Hattan DG, Jenkins MY, McDonald JT, Sundaresan PR, Wilkening VL. Evaluation of vitamin A toxicity. Am J Clin Nutr. 1990;52:183– 202.

45.

Gleghorn EE, Eisenberg LD, Hack S, Parton P, Merritt RJ. Observations of vitamin A toxicity in three patients with renal failure receiving parenteral alimentation. Am J Clin Nutr. 1986 ; 44:107– 112.

46.

Story DA, Ronco C, Bellomo R. Trace element and vitamin concentrations and losses in critically ill patients treated with continuous venovenous hemofiltration. Crit Care Med. 1999 ;27:220– 223.

47.

Fortin MC, Amyot SL, Geadah D, Leblanc M. Serum concentrations and clearances of folic acid and pyridoxal 5 phosphate during venovenous continuous renal replacement therapy. Intensive Care Med. 1999;25:594– 598.

48.

Berger MM, Shenkin A, Revelly JP, et al. Copper, selenium, zinc, and thiamine balances during continuous venovenous hemodiafiltration in critically ill patients. Am J Clin Nutr. 2004 ;80:410– 416.

49.

Maxvold NJ, Smoyer WE, Custer JR, Bunchman TE. Amino acid loss and nitrogen balance in critically ill children with acute renal failure: a prospective comparison between classic hemofiltration and hemofiltration with dialysis. Crit Care Med. 2000 ;28:1161– 1165.

50.

Frankenfield D, Reynolds N. Nutritional effect of continuous hemodiafiltration. Nutrition. 1995 ;11:388– 393.

51.

Hickman RO, Buckner CD, Clift RA, Sanders JE, Stewart, P. A modified right atrial catheter for access to the venous system in marrow transplant recipients. Surg Gynecol Obstet. 1979 ;148:871– 875.

52.

Aker SN, Cheney CL, Sanders JE, et al. Nutritional support in marrow graft recipients with single versus double lumen right atrial catheters. Exp Hematol. 1982 ;10:732– 737.

53.

Weisdorf SA, Lysne J, Wind D, et al. Positive effect of prophylactic total parenteral nutrition on long-term outcome of bone marrow transplantation. Transplantation. 1987 ;43:833– 838.

54.

Roberts S, Miller J, Pineiro L, Jennings L. Total parenteral nutrition vs oral diet in autologous hematopoietic cell transplant recipients. Bone Marrow Transplant. 2003 ;32:715– 721.

55.

Johansson J-E, Brune M, Ekman M. The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning. Bone Marrow Transplant. 2001;28:737– 742.

56.

Parker JE, Shafi T, Pagliuca A, et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol. 2002;119 :144– 154.

57.

Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003 ;102:756– 762.

58.

Iestra JA, Fibbe WE, Zwinderman AH, Romijn JA, Kromhout D. Parenteral nutrition following intensive cytotoxic therapy: an exploratory study on the need for parenteral nutrition after various treatment approaches for haematological malignancies. Bone Marrow Transplant. 1999;23:933– 939.

59.

Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562– 1568.

60.

Bensinger WI, Buckner CD. Preparative regimens. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Stem Cell Transplantation. 2^nd ed. Malden, MA: Blackwell Science, Inc; 1999:123– 134.

61.

Bearman SI. Toxicity of drugs used in stem cell transplantation regimens. In: Atkinson K, ed. Clinical Bone Marrow and Blood Stem Cell Transplantation. Boston, MA: Cambridge University Press;2000 : 829.

62.

Hill GR, Ferrara JLM. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cyokine shields in allogeneic bone marrow transplantation. Blood. 2000;95:2754– 2759.

63.

Stiff P. Mucositis associated with stem cell transplantation: current status and innovative approaches to management. Bone Marrow Transplant. 2001;27(suppl 2):S3– S11.

64.

Johansson J-E, Ekman T. Gastro-intestinal toxicity related to bone marrow transplantation: disruption of the intestinal barrier precedes clinical finds. Bone Marrow Transplant. 1997 ;19:921– 925.

65.

Sefcick A, Anderton D, Byrne JL, et al. Naso-jejunal feeding in allogeneic bone marrow transplant recipients: results of a pilot study. Bone Marrow Transplant. 2001 ;28:1135– 1139.

66.

Szeluga DJ, Stuart RK, Brookmeyer R, et al. Nutritional support of bone marrow transplant recipients: a prospective randomized clinical trial comparing total parenteral nutrition to an enteral feeding program. Cancer Res. 1987 ;47:3309– 3316.

67.

Papadopoulou A, MacDonald A, Williams MD, et al. Enteral nutrition after bone marrow transplantation. Arch Dis Child. 1997 ;77:131– 136.

68.

Roberts SR, Miller JE. Success using PEG tubes in marrow transplant recipients. Nutr Clin Pract. 1998 ;13:74– 78.

69.

Pedersen AM, Kok K, Petersen G, Nielsen OH, Michaelsen KF, Schmiegelow K. Percutaneous endoscopic gastrostomy in children with cancer. Acta Paediatr. 1999 ;88:849– 852.

70.

Barron MA, Duncan DS, Green GJ, et al. Efficacy and safety of radiologically placed gastrostomy tubes in paediatric haematology/oncology patients. Med Pediatr Oncol. 2000 ;34:177– 182.

71.

Langdana A, Tully N, Molloy E, et al. Intensive enteral nutrition support in paediatric bone marrow transplantation. Bone Marrow Transplant. 2001;27:741– 746.

72.

Hopman GD, Pena EG, Le Cessie S, Van Weel MH, Vossen JM, Mearin ML. Tube feeding and bone marrow transplantation. Med Pediatr Oncol. 2003;40:375– 379.

73.

Mulder POM, Bouman JG, Gietema JA, et al. Hyperalimentation in autologous bone marrow transplantation for solid tumors. Cancer. 1989;64:2045– 2052.

74.

Pietsch JB, Ford C, Whitlock JA. Nasogastric tube feedings in children with high-risk cancer: a pilot study. J Pediatr Hematol Oncol. 1999;21:111– 114.

75.

Altekruse SF, Swerdlow DL. The changing epidemiology of food-borne diseases. Am J Med Sci. 1996 ;311:23– 29.

76.

Smith LH, Besser SG. Dietary restrictions for patients with neutropenia: a survey of institutional practices. Oncol Nurs Forum. 2000;27:515– 520.

77.

French MR, Levy-Milne R, Zibrik D. A survey of the use of low microbial diets in pediatric bone marrow transplant programs. J Am Diet Assoc. 2001;101:1194– 1198.

78.

Ladas E. The neutropenic diet: an examination of the evidence. On-Line (Oncology Nutrition Dietetic Practice Group). 2002 ;10:1– 7.

79.

Dykewicz CA, Jaffe JE. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Morb Mortal Wkly Rep 2000 ;49(RR-10):1– 128.